Cyclomics is a Dutch health-tech startup that aims to revolutionize cancer care through faster and more reliable diagnoses. Founded in 2018 by scientists from UMC Utrecht, Cyclomics is focused on improving cancer diagnostics using liquid biopsies. Their groundbreaking solution enables the accurate detection of cancer recurrence by identifying ctDNA, a reliable biomarker found in blood samples.

This non-invasive method allows for early detection and monitoring of cancer, leading to more effective treatment. CyclomicsSeq, their novel ctDNA detection assay, offers near 100% accuracy in detecting even a single ctDNA molecule. Powered by state-of-the-art bioinformatics and AI platforms, each sequencing-read is analyzed to deliver super-accurate results.

Currently, Cyclomics is concentrating on recurring HNC (head and neck cancer) due to specific oncogenic DNA mutations in the TP53 gene. Their in vitro diagnostic (IVD) kit, CyclomicsSeq TP53, combines innovative sequencing technology with advanced analysis software for seamless integration into existing clinical workflows. In the long-term, Cyclomics plans to expand their solution to other cancer types harboring TP53 mutations.

By improving cancer diagnostics with their innovative technology, Cyclomics is dedicated to transforming cancer care for the better